HAE Haemonetics Corporation

120.37USD-2.03%Mkt Cap: 5.48B USDP/E: 53.26

Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collectio…

Institutional holders20 on file

Key Statistics

Company
Market Cap5.48B USD
Enterprise Value6.46B USD
Revenue (TTM)1.38B USD
Gross Profit787.59M USD
Net Income (TTM)97.31M USD
Revenue/Share30.07 USD
Last Price120.37 USD
Fiscal Year EndMar 2026
MR QuarterSep 2026
Employees3.0K
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)53.26
P/E (Forward)19.20
PEG1.92
EV/EBITDA17.74
EV/Revenue4.67
P/S3.96
P/B6.10
EPS (TTM)2.26 USD
EPS (Forward)6.27 USD
52W Range
51.0086% of range132.00
52W High132.00 USD
52W Low51.00 USD
Profitability
Gross Margin59.04%
Oper. Margin18.83%
EBITDA Margin26.32%
Profit Margin7.29%
ROE12.22%
ROA4.06%
ROIC10.33%
ROCE11.42%
Growth
Revenue Growth9.30%
Earnings Growth23.50%
Cash Flow & Leverage
Operating CF293.22M USD
CapEx (TTM)32.78M USD
FCF Margin21.52%
FCF Yield5.43%
Net Debt860.85M USD
Net Debt/EBITDA2.37
Net Debt/FCF2.89
Balance Sheet
Debt/Equity1.54
Current Ratio2.84
Quick Ratio1.62
Book Value/Sh19.74 USD
Cash/Share5.77 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split2:1
Split DateDec 3, 2012
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)147.18 USD
Upside (mean)+22.3%
Target Range125.00 USD – 165.00 USD
125.00+22.3% to mean165.00
# Analysts11
Ownership
Shares Out.45.54M
Float44.93M
Insiders1.27%
Institutions108.76%
Short Interest
Short Ratio5.0d
Short % Float9.25%
Short % Out.7.90%
Shares Short3.60M
Short (prev mo.)3.04M
Technical
SMA 50113.68 (+5.9%)
SMA 20081.54 (+47.6%)
Beta0.59
S&P 52W Chg12.08%
Avg Vol (30d)674.15K
Avg Vol (10d)754.13K
Technical Indicators
RSI (14)52.4
MACD1.9061
MACD Signal2.4479
MACD Hist.-0.5418
BB Upper125.45 USD
BB Middle120.98 USD
BB Lower116.51 USD
BB Width7.39%
ATR (14)3.990 USD
Vol Ratio (20d)0.64x

About Haemonetics (NYSE: HAE)

›

Haemonetics (NYSE: HAE) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 3,009 employees.

The shares were at 120.37 USD on 19 November 2026, up 63.8% over 52 weeks. Its 52-week range is 51.00 USD to 132.00 USD: the price is 8.8% below the high and 136.0% above the low.

At a market capitalisation of 5.48B USD, it trades at 53.3 times trailing earnings and 19.2 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.6, a premium of 108% for HAE.

Haemonetics reports return on equity of 12.2%, an operating margin of 18.8% and revenue up 9.3% year over year.

Its debt exceeds its cash by 860.85M USD, a debt-to-equity ratio of 1.54. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 11 analysts cover the stock, with an average rating of Buy; their mean price target of 147.18 USD is 22.3% above the current price. The next earnings report is expected on 4 February 2027.